Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
24 March 2023 - 08:00AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will host a conference call and webcast on Wednesday, March
29, 2023, at 4:30 p.m. EDT to report financial results and provide
an update on its discovery platform and pipeline, including updated
data from the ongoing Phase 1b trial of ATRC-101.
To access the conference call by telephone, please use this link
to register and receive the dial-in numbers and unique PIN to
access the call. To access the webcast, including accompanying
slides, please use this link.
The conference call registration and a live audio webcast and
accompanying slide presentation can also be accessed via the Events
section of the Company’s investor relations website at
https://ir.atreca.com/news-and-events/event-calendar. An archived
replay of the webcast will be available on the Company's website
for 30 days following the live event.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel
antibody-based immunotherapeutics generated by its differentiated
discovery platform. Atreca's platform allows access to an
unexplored landscape in oncology through the identification of
unique antibody-target pairs generated by the human immune system
during an active immune response against tumors. These antibodies
provide the basis for first-in-class therapeutic candidates, such
as our lead product candidate ATRC-101, our pipeline of lead-stage
oncology programs, and MAM01/ATRC-501, a clinical candidate
licensed to the Bill & Melinda Gates Medical Research Institute
for the prevention of malaria. A Phase 1b study evaluating ATRC-101
in multiple solid tumor cancers is currently enrolling patients.
For more information on Atreca, please visit www.atreca.com.
This release contains statements regarding matters that are not
historical facts that are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements regarding our strategy and future plans, including
statements regarding the development of ATRC-101, our pipeline of
lead-stage oncology programs, MAM01/ATRC-501, and our preclinical,
clinical, and regulatory plans, and the timing thereof. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, clinical trials,
regulatory submissions, and other matters that are described in our
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) and
available on the SEC's website at www.sec.gov, including the risk
factors set forth therein. Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Atreca, Inc.Herb CrossChief Financial Officerinfo@atreca.com
Investors:Alex Gray, firstname.lastname@example.org
Media:Julia Fuller, email@example.com
Source: Atreca, Inc.
Historical Stock Chart
From May 2023 to Jun 2023
Historical Stock Chart
From Jun 2022 to Jun 2023